{"id":"tislelizumab-cisplatin-paclitaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis)"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized anti-PD-1 monoclonal antibody that releases the brakes on T-cell-mediated anti-tumor immunity by blocking the PD-1/PD-L1 checkpoint. Cisplatin is a platinum-based alkylating agent that cross-links DNA, while paclitaxel is a taxane that stabilizes microtubules and prevents cell division. The combination leverages immunotherapy with conventional chemotherapy for enhanced anti-tumor activity.","oneSentence":"Tislelizumab blocks PD-1 to restore anti-tumor immunity, while cisplatin and paclitaxel provide direct cytotoxic chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:47.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Squamous cell carcinoma of the head and neck"}]},"trialDetails":[{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT07370337","phase":"PHASE2","title":"Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-05-12","conditions":"Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor","enrollment":50},{"nctId":"NCT07346807","phase":"PHASE2","title":"Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Tongue Squamous Cell Carcinoma","enrollment":69},{"nctId":"NCT07339488","phase":"PHASE2","title":"Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chuangzhen Chen","startDate":"2025-11-01","conditions":"Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":43},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT06010303","phase":"PHASE2","title":"A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-08","conditions":"Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage","enrollment":118},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT07111455","phase":"","title":"Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-07-22","conditions":"Locally Advanced Oral Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT05014815","phase":"PHASE2","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-11-16","conditions":"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV","enrollment":272},{"nctId":"NCT06893380","phase":"","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-10-01","conditions":"Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers","enrollment":61},{"nctId":"NCT05758389","phase":"PHASE2","title":"Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-04-01","conditions":"Head and Neck Tumors","enrollment":29},{"nctId":"NCT07147426","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-09-20","conditions":"Head &Amp; Neck Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT05880082","phase":"PHASE2","title":"PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-01-13","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT06091943","phase":"PHASE1","title":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-16","conditions":"Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT07086456","phase":"PHASE2","title":"Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy","enrollment":80},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT07046221","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Esophagus Cancer","enrollment":60},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06969612","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":21},{"nctId":"NCT04821765","phase":"PHASE2","title":"Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10-01","conditions":"Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease","enrollment":35},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06978829","phase":"PHASE2","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-03-01","conditions":"LA HNSCC","enrollment":42},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT03957590","phase":"PHASE3","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-06-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":370},{"nctId":"NCT06939127","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT06728618","phase":"PHASE2","title":"Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-12","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma","enrollment":28},{"nctId":"NCT06725498","phase":"PHASE2","title":"Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT05520619","phase":"PHASE2","title":"Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-15","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74},{"nctId":"NCT05919030","phase":"PHASE3","title":"A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":155},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT06554028","phase":"PHASE2","title":"Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-08","conditions":"Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms","enrollment":46},{"nctId":"NCT05628610","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-09-30","conditions":"Esophageal Cancer","enrollment":130},{"nctId":"NCT06383780","phase":"PHASE3","title":"Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-15","conditions":"Nasopharyngeal Carcinoma","enrollment":90},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06323369","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":154},{"nctId":"NCT05582265","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-10-28","conditions":"Head and Neck Squamous Cell Carcinomas","enrollment":537},{"nctId":"NCT06357598","phase":"PHASE4","title":"Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-01-18","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT05984342","phase":"PHASE1","title":"Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2023-08-02","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05791097","phase":"PHASE3","title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT05862168","phase":"PHASE2","title":"Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial","status":"RECRUITING","sponsor":"Weijia Fang, MD","startDate":"2023-05-08","conditions":"Oral Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05603065","phase":"PHASE4","title":"Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT05900921","phase":"PHASE2","title":"Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2023-07-01","conditions":"Advanced Squamous Non-Small-Cell Lung Cancer","enrollment":132},{"nctId":"NCT05863260","phase":"","title":"Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-11-09","conditions":"Cervical Cancer, Immune Checkpoint Inhibitor, Chemoradiotherapy","enrollment":60},{"nctId":"NCT05286957","phase":"PHASE2","title":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-06-20","conditions":"NSCLC","enrollment":60},{"nctId":"NCT05323890","phase":"PHASE2","title":"Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2022-04-20","conditions":"Advanced Esophageal Squamous Cell Cancer","enrollment":15},{"nctId":"NCT05343325","phase":"PHASE2","title":"The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC","status":"RECRUITING","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-03-09","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment","enrollment":25},{"nctId":"NCT05596890","phase":"PHASE2","title":"Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-11-30","conditions":"Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy","enrollment":50},{"nctId":"NCT05247619","phase":"PHASE2","title":"A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-06-30","conditions":"Cervical Cancer","enrollment":49},{"nctId":"NCT05449483","phase":"PHASE2","title":"Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-05-11","conditions":"Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable","enrollment":40},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT05241132","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary","status":"UNKNOWN","sponsor":"Wei Xu","startDate":"2021-11-12","conditions":"Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab","enrollment":27},{"nctId":"NCT05013268","phase":"PHASE1","title":"Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-09","conditions":"Cervical Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT04865705","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-11-10","conditions":"Stage III, Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tislelizumab + cisplatin + paclitaxel","genericName":"Tislelizumab + cisplatin + paclitaxel","companyName":"First Affiliated Hospital Xi'an Jiaotong University","companyId":"first-affiliated-hospital-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab blocks PD-1 to restore anti-tumor immunity, while cisplatin and paclitaxel provide direct cytotoxic chemotherapy. Used for Non-small cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}